New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck

The preparation of pyrazolo[1,5a]pyrimidines and their evaluation as inhibitors of lymphocyte-specific kinase (Lck) both in vitro and in vivo is described.